July 18 (Reuters) - Drug developer 9 Meters Biopharma (NMTR.O) and its units have filed for Chapter 11 bankruptcy protection, it said in a regulatory filing on Tuesday, sending its shares tumbling 66% in premarket trading.
RALEIGH, NC / ACCESSWIRE / May 30, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that the Board of Directors has accepted the resignation of John Temperato as President and Chief Executive Officer of the Company effective immediately.
RALEIGH, NC / ACCESSWIRE / May 15, 2023 / 9 Meters Biopharma, Inc. (Nasdaq:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2023.
RALEIGH, NC / ACCESSWIRE / March 28, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, upcoming milestones, and financial results for the fourth quarter and full year ended December 31, 2022.
RALEIGH, NC / ACCESSWIRE / March 15, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today the closing of its previously announced registered direct offering of 3,125,000 shares of the Company's common stock (or common stock equivalents) and warrants to purchase 6,250,000 shares of common stock at a combined purchase price of $1.60 per share of common stock (or common stock equivalent) and accompanying warrant priced at-the-market under Nasdaq rules. The warrants have an exercise price of $1.35 per share, are immediately exercisable, and expire three and one-half years following the date of issuance.
RALEIGH, NC / ACCESSWIRE / March 14, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of 3,125,000 shares of the Company's common stock (or common stock equivalents) and warrants to purchase 6,250,000 shares of common stock at a combined purchase price of $1.60 per share of common stock (or common stock equivalent) and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $1.35 per share, will be exercisable immediately following issuance, and will expire three and one-half years following the date of issuance. The closing of the offering is expected to occur on or about March 15, 2023, subject to the satisfaction of customary closing conditions.
RALEIGH, NC / ACCESSWIRE / March 7, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced that John Temperato, President and Chief Executive Officer of 9 Meters, is scheduled to present at the Oppenheimer 33rd Annual Healthcare Conference.
RALEIGH, NC / ACCESSWIRE / November 14, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced a continuing collaboration agreement with Gustave Roussy, a world-renowned cancer center in France, using 9 Meters' small molecule tight junction microbiome modulator NM-102. NM-102 is presumed to prevent gut microbial metabolites and antigens from trafficking into the systemic circulation.
RALEIGH, NC / ACCESSWIRE / November 8, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided an overview of its recent achievements, important upcoming milestones, and financial results for the third quarter ended September 30, 2022.